Misplaced Pages

#397602

24-761: (Redirected from Sandoz Prize ) Prizes for immunology [REDACTED] This article relies largely or entirely on a single source . Relevant discussion may be found on the talk page . Please help improve this article by introducing citations to additional sources . Find sources:   "Novartis Prizes for Immunology"  –  news   · newspapers   · books   · scholar   · JSTOR ( January 2020 ) The Novartis Prizes for Immunology were established in 1990 by Sandoz to honour outstanding research in immunology, and expanded to their current form in 1992. Prizes for basic and clinical immunology are awarded every 3 years. A special prize

48-437: A Time magazine feature. Research on LSD peaked in the 1950s and early 1960s. The CIA purchased quantities of LSD from Sandoz for use in its illegal human experimentation program known as MKUltra . Sandoz withdrew the drug from the market in 1965. The drug became a cultural novelty of the 1960s after psychologist Timothy Leary at Harvard University began to promote its use for recreational and spiritual experiences among

72-621: A beekeeper. He received his B.Sc. and M.Sc. from the Hebrew University of Jerusalem , and his Ph.D. from the Weizmann Institute. He is mainly known for his studies on T cells and his pioneering work on chimeric antigen receptors . His work has been the basis of the development of a cancer immunotherapy , involving genetic modifications of T lymphocytes extracted from a cancer patient to produce chimeric antigen receptor (CAR) T-Cells, which are then injected back into

96-516: A curfew of several hours was imposed. No people suffered acute harm, with the exception of three people with pre-existing asthma who required hospitalization. However, the toxins found their way into the Rhine via the extinguishing water, where they caused a large number of fish to die off. On November 11, 1986, the analysis of water samples proved that at the same time as the Rhine was being polluted by

120-808: A single global brand, reestablishing the name Sandoz as a division of Novartis. The Amifarma S.L. production plant in Palafolls, located near Barcelona, Spain was also acquired. In February 2005, Sandoz acquired over Hexal AG and Eon Labs. The integration into Sandoz created the second largest generics group in the world and the largest on the German market with annual sales of 7.6 billion US dollars (2008) and over 23,000 employees in 130 countries. The headquarters have been in Holzkirchen since 2005. Sandoz's Swiss administrative headquarters are in Rotkreuz ZG in

144-543: The Swedish crisp bread producer Wasa in 1982. In 1986, Velsicol Chemical Corporation acquired the agrochemicals division of Sandoz. In 1994, Sandoz bought Gerber Products Company, expanding its research into biopharmacueticals. In 1995, the specialty chemicals division became an independent company under the name Clariant , based in Muttenz . On December 20, 1996, the merger of Sandoz and Ciba-Geigy led to

168-532: The cause. Subsequent trials, however, resulted in no conviction. The plant now belongs to Clariant . To this day, the landfill left after the fire continues to pollute the groundwater in Muttenz and is actively monitored by Novartis, as the legal successor to Sandoz, and the environmental authorities of the Canton of Basel-Landschaft. To commemorate the spill, there is a plastic market table by Bettina Eichin in

192-751: The cloister of Basel Munster . Zelig Eshhar Zelig Eshhar is an Israeli immunologist at the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center . He was Chairman of the Department of Immunology at the Weizmann Institute twice, in the 1990s and 2000s. Zelig Lipka (later Eshhar) grew up in Rehovot . After his IDF service in Nahal , he joined Kibbutz Yad Mordechai , where he became

216-475: The contaminated extinguishing water from the Sandoz area, 400 kg of atrazine , a herbicide, had been discharged into the Rhine from the neighboring chemical company Ciba-Geigy. The official investigation report came to the conclusion (only " on the basis of theoretical considerations ") that when pallets were packed with Prussian blue, incorrect handling of a hot air blower led to a hot spot, which could be

240-624: The creation of Novartis. The Sandoz brand name was then only used in the pharmaceutical business for over-the-counter medicines. The former company name Sandoz was reactivated in May 2003 with the merger of the globally differently named generics companies of the parent company Novartis under the uniform brand name Sandoz. In addition to the name, the company logo used before the merger was also adopted. In 2002, Sandoz acquired Lek Pharmaceuticals d.d., Slovenia's largest pharmaceutical company. In 2003, Novartis united its global generics businesses under

264-440: The first time the same year. As early as 1895, the first pharmaceutical substance called antipyrine was produced to reduce fever. In 1899 they started producing saccharin . In 1917, Sandoz entered pharmaceutical research when Arthur Stoll (1887–1971) was hired, and, in 1929, Calcium Sandoz was introduced, laying the foundation research into modern calcium therapy. In 1918, Arthur Stoll isolated ergotamine from ergot ;

SECTION 10

#1732776078398

288-421: The general public. In 1939, Kern & Sandoz became Sandoz Ltd., a name it operated under for nearly sixty years. In 1963, Sandoz acquired Biochemie GmbH, which was producing and supplying scarce, urgently needed acid-resistant penicillin. In 1967, Sandoz merged with Wander AG and diversified into the dietetics business with Ovomaltine and Isostar . In 1972, Sandoz acquired Delmark, Wasabröd, Wasa,

312-441: The generic (topical) dermatology business. In November 2018, it was announced that Novartis would convert Sandoz into an independent entity over the next two years. In March 2019, it was announced that CEO Richard Francis had resigned for personal reasons and that Francesco Balestrieri, Sandoz's European head, had taken over management ad interim. Richard Saynor was appointed as CEO later in 2019. In August 2022, Novartis said

336-677: The municipality of Risch in the canton of Zug. In 2006, Omnitrope , a recombinant human growth hormone, was approved by the European Medicines Agency (EMA) and also became the first biosimilar to receive approval from the FDA. In 2007, the first complex biosimilar, Binocrit was approved in the EU. In 2009, Sandoz acquired EBEWE Pharma's specialty generic injectables division and in 2010, acquired Oriel Therapeutics. In 2012, Sandoz acquired Fougera Pharmaceuticals, entering

360-533: The new headquarters in Basel, Switzerland. On November 1, 1986, a major fire broke out in a warehouse containing 1,350 tonnes (2,980,000 lb) of chemicals in what was then Sandoz in Schweizerhalle . The thick smoke, the stench and the unknown composition of the combustion gases caused the authorities in the neighboring communities to alert the population early in the morning with a general siren alarm and

384-589: The next month, resulting in Novartis shareholders receiving one Sandoz share for every five Novartis shares. Sandoz was listed on the SIX Swiss Exchange with a market capitalization between $ 18 billion and $ 25bn. On October 4, 2023, Novartis completed the spin-off of Sandoz as a stand-alone company. In January 2024, Sandoz announced it would acquire biosimilar drug for vision Cimerli For $ 170 million from Coherus BioSciences. The acquisition

408-641: The original on 29 August 2018 . Retrieved 29 August 2018 . References [ edit ] ^ "The Prizes" . Novartis Prizes for Immunology . 5 November 2012 . Retrieved 29 August 2018 . Retrieved from " https://en.wikipedia.org/w/index.php?title=Novartis_Prizes_for_Immunology&oldid=1186959757 " Categories : Medicine awards Novartis Hidden categories: Articles with short description Short description matches Wikidata Articles needing additional references from January 2020 All articles needing additional references Pages using interlanguage link with

432-713: The patient in a process called adoptive cell transfer , that produced startlingly good results in clinical trials in the mid-2010s and millions of dollars of investment. In 2013 Eshhar was awarded the CAR Pioneering award by the ATTACK European Consortium as well as the European Society of Gene & Cell Therapy Outstanding Achievement Award. In 2014 he shared the Massry Prize with Steven Rosenberg and James P. Allison and

456-517: The spin-off of Sandoz into a standalone company would be completed by the end of 2023. As part of the spin-off, Sandoz announced in June 2023 it would move its headquarters from Holzkirchen , Germany to Basel, Switzerland. In July 2023, Sandoz launched a biosimilar version of AbbVie Inc 's Humira , under the label, Hyrimoz . In September 2023, Novartis announced that the spin-off had been approved by its shareholders and that it would be completed by

480-412: The substance was eventually used to treat migraine and headaches and was introduced under the trade name Gynergen in 1921. In 1938 Albert Hofmann produced the synthetic substance lysergic acid diethylamide , better known as LSD. The psychoactive properties of this preparation were nevertheless not discovered until 1943, when Hofmann ingested a small amount by accident. From 1947 to the mid-60s, LSD

504-525: The wikidata parameter Interlanguage link template existing link Sandoz The company was founded in 1886 by Alfred Kern (1850–1893) and Edouard Sandoz (1853–1928) in Basel (Switzerland) under the name Chemiefirma Kern und Sandoz . Initially the company focused on production of dyes namely alizarin blue and auramine . When Kern died, the company changed its name to Chemische Fabrik vormals Sandoz in 1895 and began producing pharmaceuticals for

SECTION 20

#1732776078398

528-1622: Was awarded in 2004. Sandoz Prize for Immunology [ edit ] 1990 Max Cooper , Jacques Miller Novartis Prize for Basic Immunology [ edit ] 2016 John Kappler , Philippa Marrack , Harald von Boehmer 2013 Robert Coffman  [ de ] , Tim Mosmann  [ de ] 2010 Michael Bevan  [ Wikidata ] 2007 Fred Alt , Klaus Rajewsky , Fritz Melchers  [ de ] 2004 Ralph Steinman 2001 Klas Kärre , Lorenzo Moretta  [ Wikidata ] , Wayne Yokohama  [ Wikidata ] 1998 Tak Mak 1995 Melvin Cohn , Kevin Lafferty  [ Wikidata ] , Avrion Mitchison , David Talmage 1992 Jack Strominger Novartis Prize for Clinical Immunology [ edit ] 2016 Zelig Eshhar , Carl June , Steven Rosenberg 2013 James Allison 2010 Charles Dinarello , Jürg Tschopp 2007 John Schiller , Doug Lowy , Ian Frazer 2004 Hugh McDevitt 2001 Alain Fischer 1998 Barry Bloom , George Bellamy Mackaness , Andrew McMichael 1995 Robert Schwartz , Thierry Boon 1992 Tadamitsu Kishimoto , Toshio Hirano Special Novartis Prize for Immunology [ edit ] 2004 Leonard Herzenberg See also [ edit ] List of medicine awards Source [ edit ] "Laureates" . Novartis Prizes for Immunology . 3 October 2011. Archived from

552-674: Was completed in March 2024. In February 2024, Sandoz US and its subsidiary Fougera Pharmaceuticals Inc. - indirect subsidiaries of Sandoz Group AG reached a USD 265 million settlement agreement in the US related to a generics direct purchaser class action lawsuit. In April 2024, Sandoz reached an agreement with Amgen to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved Sandoz denosumab biosimilars. In November 2024, Sandoz inaugurated

576-459: Was sold by Sandoz under the name Delysid . It was marketed as a treatment for a wide variety of mental ailments , ranging from alcoholism to sexual deviancy . Sandoz suggested in its marketing literature that psychiatrists take LSD themselves, to gain a better subjective understanding of the schizophrenic experience, and many did exactly that and so did other scientific researchers. The Sandoz product received mass publicity as early as 1954, in

#397602